Adverse effects of dupilumab in chronic rhinosinusitis with nasal polyps. Case report and narrative review

Effetti avversi di dupilumab nel trattamento della rinosinusite cronica con poliposi nasale

Letizia Nitro, Antonio Mario Bulfamante, Cecilia Rosso, Alberto Maria Saibene, Flavio Arnone, Giovanni Felisati, Carlotta Pipolo
Otolaryngology Unit, Santi Paolo e Carlo Hospital, Department of Health Sciences, Università degli Studi di Milano, Milan, Italy

SUMMARY
Herein we review the current literature on the adverse effects related to biological therapy with the monoclonal antibody dupilumab in patients with type 2 inflammation prevalent phenotype chronic rhinosinusitis with nasal polyps (CRSwNP). Our review shows that the side effects of dupilumab may be linked to the prevalent type 2 inflammation phenotype (asthma, dermatitis, CRSwNP). We also report the first case of cutaneous rash as a side effect of dupilumab in a patient with CRSwNP.

KEY WORDS: dupilumab, chronic rhinosinusitis with nasal polyps, type 2 inflammation, cutaneous rash, adverse effect

INTRODUCTION
The prevalence of chronic rhinosinusitis (CRS) in the world population is estimated at 11-15% with an average of 11% in European countries. CRS has significant impact on patients’ quality of life (QoL) and inevitably leads to a burdensome effect on healthcare costs in addition to social-economic impact by reducing individual productivity.

The very recent introduction of targeted therapies based on the use of monoclonal antibodies has significantly modified and improved the outcomes of these patients. Dupixent® (dupilumab, Sanofi Genzyme) is a fully human monoclonal antibody that acts on the alpha subunit of the interleukin-4 receptor (IL 4Rα), and is capable of inhibiting the action of both IL-4 and IL-13. Its administration has been approved in the EU since October 2020 for the treatment of severe CRS associated with nasal polyps (severe CRSwNP). Previous approval by the FDA for its use in severe asthma and atopic dermatitis date to 2018, and there is now substantial data in the literature on the adverse effects (AE) of subcutaneous treatment with dupilumab.

In CRSwNP, this therapeutic option is suitable for selected patients who have a type 2 inflammation pattern-related endotype. Among the different criteria for inclusion, the therapeutic response and tolerability of the patient are of utmost importance. Dupilumab has been shown to be effective in reducing polyp size and nasal symptoms, with a positive impact on QoL. However, the therapeutic benefit should be balanced against the potential adverse effects associated with the use of this biological drug.
Several clinical studies have reported adverse effects related to the use of dupilumab in patients with CRSwNP. Furthermore, a major risk in developing side effects is described in comparison to the control group treated with placebo. The most frequent are, respectively, nasopharyngitis, injection site reaction and headache. Less frequently episaxis, lack of improvement, or worsening of nasal polyps, arthralgia, asthma or worsening of asthma have been reported.

To the best of our knowledge there are no reported cases of increased eosinophilia or ophthalmological or dermatological manifestations in patients treated with dupilumab for exclusive CRSwNP.

### Authors’ experience - Case report

Among 20 patients treated in our institution with dupilumab since January 2021, a single adverse event (AE) emerged. The patient reporting the AE was a 50-year-old male patient, with a confirmed diagnosis of CRSwNP, who had undergone multiple Endoscopic Sinus Surgeries (ESS) in the previous years (the last in 2011). The patient’s comorbidities included bronchial asthma (pulmonary function tests show a FEV₁ 59%, FVC 93%, positive bronchial reversibility test with salbutamol and a fraction of nitric oxide exhaled (FeNO) of 63% with poorly controlled symptoms by inhalation therapy, intolerance to acetylsalicylic acid (ASA), polyposis of the stomach and gastric body, prick tests negative for inhalant allergic diathesis and no prior episodes of dermatitis.

The patient underwent ENT evaluation in March 2021 for recurrence of persistent hyposmia and chronic nasal bilateral obstruction that was non-responsive to oral and topical steroids. Endoscopic evaluation (OLYMPUS, ENDOEYE™ LF-V) provided evidence of complete nasal obstruction due to bilateral polypoid neoformations (NPS average score of 8).

During ENT evaluation, the SNOT-22 questionnaire was administered with a total score of 89/110; olfactometry using identification Sniffin’ Sticks (Burghart®) scored 3/12 and 4-Phase rhinomanometry values of 0.22 to the right side and 0.72 on the left side were observed. After evaluation of blood eosinophils (0.71 x 10⁹/L, r.v. 0.00-0.50 x 10⁹/L) and nasal cytology (presence of eosinophils: 12/hpf) that confirmed the presence of type 2 lead inflammation, treatment with dupilumab (300 mg) was initiated in May 2021 and followed by one injection every two weeks.

The first follow-up was performed after 1 month of treatment; the patient reported clear subjective clinical improvement (SNOT-22: 10 points), improvement of the endoscopic nasal findings with NPS of 4 (2 + 2), performance...
at the Sniffin’ Stick test (Burghart®) with recognition of 14 of 16 items and rhinomanometry values of 1.06 cm H₂O/l/s on the right and 1.18 cm H₂O/l/s on the left. However, the appearance of pruritus accompanied by a skin rash localised on the caudal surfaces of the body (mainly localised on the lower limbs and groin) appeared at 2 weeks after the first administration, 1 day after the second administration of dupilumab (Figs. 1A-C, 2). After administration of antihistamine therapy (bilastine, 20 mg BID) with only transient benefit, the patient was sent for dermatological evaluation with diagnosis of irritative dermatitis and confirmation of the current therapy with addition of topical skin therapy with emollients. No other adverse effects (conjunctival inflammation, nasopharyngitis, or injection site inflammation were present). Blood work showed an increase of eosinophilia (0.90 x 10⁹/L, r.v. 0.00-0.50 x 10⁹/L). Adverse event reporting to the national authorities was promptly undertaken.

In July 2021 (after 3 months of dupilumab therapy), due to the persistence of cutaneous rash and worsening of pruritus, and despite the current local and systemic therapy, treatment with dupilumab was interrupted. After discontinuation, the patient reported rapid disappearance of the cutaneous manifestation and resolution of pruritus at one month after treatment discontinuation.

**Adverse effects in atopic dermatitis (AD)**

Atopic dermatitis is a relapsing inflammatory chronic disease. It affects 3 to 10% of adults and 10 to 20% of children. Dupilumab has shown encouraging results in the treatment of controlled moderate-to-severe forms of AD that are resistant to treatments such as phototherapy, oral corticosteroids and immunosuppressants. In addition, dupilumab allows a substantial reduction of toxic effects in comparison with other therapies.

Treatment-emergent AEs of dupilumab therapy are defined according to the Medical Dictionary for Regulatory Activities (MedDRA).

The most frequently observed AEs can be divided into infectious and non-infectious. Among infectious AEs, nasopharyngitis, upper respiratory tract infections, conjunctivitis and Herpes virus skin infections have been reported. Injection-site reactions, exacerbation of AD, headache and allergic conjunctivitis are the main non-infectious side effects reported in the literature. Moreover, rare AEs such as facial redness, alopecia, arthralgia, itching and urticarial-like rash typically localised in head and neck region have been described.

According to many studies, conjunctivitis seems to be the only specific side effect related to dupilumab in patients with AD. According to Wollemberg et al., bilateral conjunctivitis occurred in 25-50% of their patients with AD treated with dupilumab. However, the pathological mechanism is not fully understood. Indeed, prescription of biological therapy and ocular manifestations show a temporal but not causal relation.

Cutaneous manifestations have been reported as side effects during the use of dupilumab in patients with AD. These include, rash-like forms which have been described exclusively on the acral portions of the body (mainly face and upper limbs). No patient has shown involvement of caudal portions.
Adverse effects in asthma

The efficacy and safety of dupilumab in treatment of asthma has been assessed by several studies\textsuperscript{14,27,38-40}. Approximately 20\% of patients with moderate-to-severe disease show uncontrolled symptoms with maximal standardised therapies\textsuperscript{27}. The most frequent side effects, occurring in variable percentage of 5-13\% in patients with asthma treated with dupilumab are injection-site reactions\textsuperscript{14,27,38}. The appearance of blood eosinophilia may also be related to dupilumab therapy and is associated with an augmented risk of worsening of pre-existing hypereosinophilia symptoms (e.g. chronic eosinophilic pneumonia)\textsuperscript{8,27,41}. In many studies upper respiratory tract (such as nasopharyngitis and sinusitis) and urinary infections are reported more frequently with dupilumab compared to placebo\textsuperscript{27,38}. Influenza, headache and back pain are also mentioned as side effects of dupilumab therapy in asthmatic patients\textsuperscript{14,27,38}. Conjunctivitis is rarely mentioned as an adverse effect in patients with asthma and no cause-effect relation has been established\textsuperscript{27,38}. To the best of our knowledge, the appearance of skin manifestations (except for erythema localised in the injection site reactions) in dupilumab-treated asthma patients has not been reported.

Discussion

Biological therapies based on the use of monoclonal antibodies such as dupilumab show encouraging results in the treatment of comorbidities related to type 2 inflammation\textsuperscript{21}. In patients with CRSwNP, dupilumab has been shown to improve symptom scores\textsuperscript{17,42}, eosinophilic and IgE blood counts\textsuperscript{7}, and endoscopic/radiological findings\textsuperscript{17,21}. The recent introduction of biological therapy with dupilumab for CRSwNP was accompanied by different types of side effects in type 2 inflammation-related diseases. At present, the effort of several authors to standardise those AEs and assess the safety of dupilumab seems to show some shortcomings in terms of concordance and identification of specific AEs in patients with CRSwNP. The safety and efficacy of this therapy have been confirmed by many studies, but side effects in patients with CRSwNP are nonetheless poorly described in the literature. In the LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52 multicentre studies, the most commonly reported AEs were nasopharyngitis, lack of improvement of nasal polyps and asthma, headache, epistaxis and injection-site reactions\textsuperscript{21}. Likewise, according to a meta-analysis by Chong et al. in patients with CRSwNP, there is a low and uncertain increase of the risk of developing nasopharyngitis compared to the placebo group\textsuperscript{22}. The randomised, double-blind, placebo-controlled parallel-group study by Bachert et al. in 2016 was one of the few which investigated the side effects of dupilumab in CRSwNP with and without other comorbidities (50\% of the sample suffered from asthma) with evidence of AEs in 25 of 30 patients in the placebo group and in all 30 patients in the dupilumab group. The most frequent AEs described were nasopharyngitis, injection site reactions (7 and 40\%, respectively), and headache\textsuperscript{17}.

Although there is agreement about dupilumab-related AEs in patients with CRSwNP; there is a lack of studies focusing on the main side effects of therapy with dupilumab in patients with CRS with or without other comorbidities. Noticeably, different expressions of type 2 inflammation patterns seem to show distinct side effects, and in fact most of the cutaneous adverse effects described in the literature have been reported in patients with AD or other cutaneous type 2 inflammation manifestations\textsuperscript{33}. The description of itching and urticarial-like rash is only referred in literature to patients with AD, as a side effect of dupilumab administration\textsuperscript{33,36,43}. Deleuran et al. in their clinical trial stated that cutaneous side effects, such AD, should be included in the most common AEs in those patients\textsuperscript{44}.
The Food Drug Administration (FDA) and Kim et al. reported that the appearance of generalised urticaria is seen in < 1% of patients who received dupilumab and only in clinical trials on AD. Furthermore, it is interesting that these clinical features tend to appear exclusively on the acral portions of the body (trunk, upper limbs, face and neck), while in the literature no forms localised to the lower limbs and inguinal region have been described. Our clinical case is the first to describe a lower limb dermatitis in a patient after the administration of dupilumab for CRSwNP. In our experience, only interruption of dupilumab therapy allowed for resolution of pruritus and skin rash, despite antihistamine treatment. It has to be noted that this single report of a patient with a skin AE in the context of CRSwNP is an exception to the general trend linking AE to the specific type 2 inflammation-related disease.

This review of the current literature on the safety of dupilumab highlights that different type 2 inflammation-related diseases seem to show different adverse effects. In addition, our review has shown that different studies focusing on the same phenotype of type 2 inflammation show no concordance in terms of AE reported.

Conclusions
Herein, we presented the first case report of a lower limb cutaneous side effect related to therapy with dupilumab for CRSwNP. Narrative review of the literature showed that the side effects of dupilumab may be specific to the prevalent phenotype of type 2 inflammation (asthma, dermatitis, CRSwNP) and further studies will be needed to establish which AEs are more likely in each subgroup and define their pathogenetic mechanisms.

Conflict of interest statement
The authors declare no conflict of interest.

Funding
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Authors’ contributions
LN: study design, article search and selection, data extraction and drafting of the article. CR, FA and AMB: drafting of the article. AMS and CP: study design, critical revision of the article.

References
1. Fokkens WJ, Lund VJ, Mullol J, et al. EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otolar-

yanologists. Rhinology 2012;50:1-12. https://doi.org/10.4193/Rhino12.000
2. Jarvis D, Newson R, Lotvall J, et al. Asthma in adults and its association with chronic rhinosinusitis: the GA2LEN survey in Europe. Allergy 2012;67:91-98. https://doi.org/10.1111/j.1398-9995.2011.02709.x
3. Hastan D, Fokkens WJ, Bachert C, et al. Chronic rhinosinusitis in Europe—an underestimated disease. A GA-2LEN study. Allergy 2011;66:1216-1223. https://doi.org/10.1111/j.1398-9995.2011.02646.x
4. Chung JH, Lee YJ, Kang TW, et al. Altered quality of life and psychological health (SCL-90-R) in patients with chronic rhinosinusitis with nasal polyps. Ann Otol Rhinol Laryngol 2015;124:663-670. https://doi.org/10.1177/000348941557618
5. Bhattacharyya N, Villemune S, Joish VN, et al. Cost burden and resource utilization in patients with chronic rhinosinusitis and nasal polyps. Laryngoscope 2019;129:1969-1975. https://doi.org/10.1002/lary.27852
6. Bachert C, Bhattacharyya N, Desrosiers M, et al. Burden of disease in chronic rhinosinusitis with nasal polyps. J Asthma Allergy 2021;14:127-134. https://doi.org/10.2147/AAA.S290424
7. Jonstam K, Swanson BN, Mannent LP, et al. Dupilumab reduces local type 2 pro-inflammatory biomarkers in chronic rhinosinusitis with nasal polyposis. Allergy 2019;74:743-752. https://doi.org/10.1111/all.13685
8. Wenzel S, Ford L, Pearlman D, et al. Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med 2013;368:2455-2466. https://doi.org/10.1056/NEJMoa1304048
9. European Medicines Agency. Annex I. Summary of product characteristics [dupilumab]. https://www.ema.europa.eu/en/documents/product-information/dupixent-epar-product-information_en.pdf. Accessed on 19 September 2019.
10. Bachert C, Zhang N, Cavaliere C, et al. Biologics for chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol 2020;145:725-739. https://doi.org/10.1016/j.jaci.2020.01.020
11. Bachert C, Zhang L, Gevaert P. Current and future treatment options for adult chronic rhinosinusitis: focus on nasal polyposis. J Allergy Clin Immunol 2015;136:1431-1440. https://doi.org/10.1016/j.jaci.2015.10.010
12. Halling A-S, Loft N, Silverberg JI, et al. Real-world evidence of dupilumab efficacy and risk of adverse events: a systematic review and meta-analysis. J Am Acad Dermatol 2021;84:139-147. https://doi.org/10.1016/j.jaad.2020.08.051
13. Blauvelt A, de Bruin-Weller M, Gooderham M, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017;389:2287-2303. https://doi.org/10.1016/S0140-6736(17)31191-1
14. Wenzel S, Castro M, Corren J, et al. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. Lancet 2016;388:31-44. https://doi.org/10.1016/S0140-6736(16)30307-5
15. Kartush AG, Schumacher JK, Shah R, et al. Biologic agents for the treatment of chronic rhinosinusitis with nasal polyps. Am J Rhinol Allergy 2019;33:203-211. https://doi.org/10.1177/1945892418814768
16. Fokkens WJ, Lund V, Bachert C, et al. EUFOREA consensus on biologics for CRSwNP with or without asthma. Allergy 2019;74:2312-2319. https://doi.org/10.1111/all.13875
17. Bachert C, Mannent L, Naclerio RM, et al. Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis
and nasal polyposis: a randomized clinical trial. JAMA 2016;315:469-479. https://doi.org/10.1001/jama.2015.19330
18 Gallo S, Russo F, Mozmanica F, et al. Prognostic value of the Sinonasal Outcome Test 22 (SNOT-22) in chronic rhinosinusitis. Acta Otorhinolaryngol Ital 2020;40:113-121. https://doi.org/10.14639/0392-100X-N0364
19 Busse W, Maspero JF, Ketelaris CH, et al. Dupilumab improves SNOT-22 scores in asthma patients with chronic rhinosinusitis or nasal polyposis (CRSwNP) in LIBERTY ASTHMA QUEST. Eur Respir J 2018;52. http://doi.org/10.1183/13993003.congress-2018.PA1125
20 Bachert C, Helliings PW, Mullol J, et al. Dupilumab improves health-related quality of life in patients with chronic rhinosinusitis with nasal polyposis. Allergy 2020;75:148-157. https://doi.org/10.1111/all.13984
21 Bachert C, Han JK, Desrosiers M, et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet 2019;394:1638-1650. https://doi.org/10.1016/S0140-6736(19)31881-1
22 Chong L-Y, Piromchai P, Sharp S, et al. Biologicals for chronic rhinosinusitis. Cochrane Database Syst Rev 2020;2:CD015313. https://doi.org/10.1002/14651858.CD015313.pub2
23 Bachert C, Zinreich SJ, Helliings PW, et al. Dupilumab reduces opacification across all sinuses and related symptoms in patients with CRSwNP. Rhinology 2020;58:10-17. https://doi.org/10.4193/Rhin18.282
24 Iqbal IZ, Kao SS-T, Ooi EH. The role of biologics in chronic rhinosinusitis: a systematic review. Int Forum Allergy Rhinol 2020;10:165-174. https://doi.org/10.1002/air.22473
25 Desrosiers M, Mannent LP, Amin N, et al. Dupilumab reduces systemic corticosteroid use and sinonasal surgery rate in CRSwNP. Rhinology 2021;59:301-311. https://doi.org/10.4193/Rhin20.415
26 Mullol J, Laidlaw TM, Bachert C, et al. Efficacy and safety of dupilumab in patients with uncontrolled severe CRSwNP and a clinical diagnosis of NSAID-ERD: results from two randomized placebo-controlled phase 3 trials. Allergy 2022;77:1231-1244. https://doi.org/10.1111/all.15067
27 Castro M, Corren J, Pavord ID, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med 2018;378:2486-2496. https://doi.org/10.1056/NEJMoa1804092
28 Akinlade B, Guttman-Yassky E, de Bruin-Wellmer E, et al. Conjugativists in dupilumab clinical trials. Br J Dermatol 2019;181:459-473. https://doi.org/10.1111/bjd.17869
29 Simpson EL, Biebert T, Guttman-Yassky E, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med 2016;375:2335-2348. https://doi.org/10.1056/NEJMoa1616020
30 Guttman-Yassky E, Bissonnette R, Unger B, et al. Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis. J Allergy Clin Immunol 2019;143:155-172. https://doi.org/10.1016/j.jaci.2018.08.022
31 Seegräber M, Srouj J, Walter A, et al. Dupilumab for treatment of atopic dermatitis. Expert Rev Clin Pharmacol 2018;11:467-474. https://doi.org/10.1080/17512433.2018.1449642
32 Gooderham MJ, Hong HC-H, Eshtiaghi P, et al. Dupilumab: a review of its use in the treatment of atopic dermatitis. J Am Acad Dermatol 2018;78:S28-36. https://doi.org/10.1016/j.jaad.2017.12.022
33 Thaci D, Simpson EL, Beck LA, et al. Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial. Lancet 2016;387:40-52. https://doi.org/10.1016/S0140-6736(15)00388-8
34 Fargnoli MC, Esposito M, Ferrucci S, et al. Real-life experience on effectiveness and safety of dupilumab in adult patients with moderate-to-severe atopic dermatitis. J Dermatol Treat 2021;32:507-513. https://doi.org/10.1080/09546634.2019.1682503
35 de Wijs LEM, Nguyen NT, Kunkeler ACM, et al. Clinical and histopathological characterization of paradoxical head and neck erythema in patients with atopic dermatitis treated with dupilumab: a case series. Br J Dermatol 2018;183:745-749. https://doi.org/10.1111/bjd.18730
36 Thibodeaux Q, Smith MP, Ly K, et al. A review of dupilumab in the treatment of atopic diseases. Hum Vaccin Immunother 2019;15:2129-2139. https://doi.org/10.1080/21645515.2019.1582403
37 Wollenberg A, Ariens L, Thurau S, et al. Conjugativists occurring in atopic dermatitis patients treated with dupilumab—clinical characteristics and treatment. J Allergy Clin Immunol Pract 2018;6:1778-1780. e1. https://doi.org/10.1016/j.jaip.2018.01.034
38 Rabe KF, Nair P, Brusselle G, et al. Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Engl J Med 2018;378:2475-2485. https://doi.org/10.1056/NEJMoa1804093
39 Busse WW, Maspero JF, Rabe KF, et al. Liberty Asthma QUEST: phase 3 randomized, double-blind, placebo-controlled, parallel-group study to evaluate dupilumab efficacy/safety in patients with uncontrolled, moderate-to-severe asthma. Adv Ther 2018;35:737-748. https://doi.org/10.1007/s12325-018-0702-4.
40 Agache I, Beltran J, Akdis C, et al. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma. Allergy 2020;75:1023-1042. https://doi.org/10.1111/all.14221
41 Wenzel SE. Asthma phenotypes: the evolution from clinical to molecular approaches. Nat Med 2012;18:716-725. https://doi.org/10.1038/nm.2678
42 Bachert C, Helliings PW, Mullol J, et al. Dupilumab improves patient-reported outcomes in patients with chronic rhinosinusitis with nasal polyps and comorbid asthma. J Allergy Clin Immunol Pract 2019;7:2447-2449.e2. https://doi.org/10.1016/j.jaip.2019.03.023
43 Kim J, Naclerio R. Therapeutic potential of dupilumab in the treatment of chronic rhinosinusitis with nasal polyps: evidence to date. Ther Clin Risk Manag 2020;16:31-37. https://doi.org/10.2147/TCRM.S210648
44 Deleuran M, Thaci D, Beck LA, et al. Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study. J Am Acad Dermatol 2020;82:377-388. https://doi.org/10.1016/j.jaad.2019.07.074
45 FDA. Dupixten® (dupilumab) injection, for subcutaneous use: US prescribing information. 2017. US Food and Drug Administration (https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761055lbl.pdf). Accessed on March 2017.